Results 11 to 20 of about 11,284,409 (311)

Pyrylium based derivatization imaging mass spectrometer revealed the localization of L-DOPA.

open access: yesPLoS ONE, 2022
Simultaneous imaging of l-dihydroxyphenylalanine (l-DOPA), dopamine (DA) and norepinephrine (NE) in the catecholamine metabolic pathway is particularly useful because l-DOPA is a neurophysiologically important metabolic intermediate.
Shu Taira   +6 more
doaj   +1 more source

Effects of L-dopa and p-coumaric acid combination on oxidative stress, DNA damage, and mitochondrial apoptosis in neuroblastoma cells

open access: yesBangladesh Journal of Pharmacology, 2023
This study aimed to investigate the effects of levodopa (L-dopa), p-coumaric acid, and combinations in the neuroblastoma (N1E-115) cell. L-dopa and L-dopa plus p-coumaric acid group caused oxidative stress by increasing 12.5 and 3.7-fold in superoxide ...
Nebiye Pelin Turker, Elvan Bakar
doaj   +1 more source

L-dopa and arousal [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 1974
In 10 patients with Parkinsonism, treatment with L-dopa was associated with a rise in the skin conductance level and its fluctuations, an increased electromyographic activity in the frontalis muscle, and with faster reaction times. The change of skin conductance in response to a loud noise also increased and its habituation to the repetition of the ...
T B, Horvath, R A, Meares
openaire   +2 more sources

Irreversible incorporation of L-dopa into the C-terminus of α-tubulin inhibits binding of molecular motor KIF5B to microtubules and alters mitochondrial traffic along the axon

open access: yesNeurobiology of Disease, 2021
L-dopa is the most effective drug used to date for management of Parkinson's disease symptoms. Unfortunately, long-term administration of L-dopa often results in development of motor disorders, including dyskinesias.
Agustina Zorgniotti   +3 more
doaj   +1 more source

GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming

open access: yesNeurobiology of Disease, 2020
Levo-dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease; however, most patients develop uncontrollable abnormal involuntary movements known as L-DOPA-induced dyskinesia.
Haruo Nishijima   +10 more
doaj   +1 more source

An Overview of Methods for L-Dopa Extraction and Analytical Determination in Plant Matrices

open access: yesSeparations, 2022
L-dopa is a precursor of dopamine used as the most effective symptomatic drug treatment for Parkinson’s disease. Most of the L-dopa isolated is either synthesized chemically or from natural sources, but only some plants belonging to the Fabaceae family ...
Carmen Tesoro   +5 more
doaj   +1 more source

Polymorphism of the Dopa-Decarboxylase Gene Modifies the Motor Response to Levodopa in Chinese Patients With Parkinson's Disease

open access: yesFrontiers in Neurology, 2020
Levodopa (L-DOPA) is the most effective drug for Parkinson's disease (PD). However, the response to L-DOPA remains individually variable, which hampers the practical value of L-DOPA in the clinic. Genetic factors play a role in L-DOPA efficacy.
Lanting Li   +6 more
doaj   +1 more source

Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39. [PDF]

open access: yesPLoS ONE, 2014
OBJECTIVE: This study aimed to investigate the influence of low-dose levodopa (L-DOPA) on neuronal cell death under oxidative stress. METHODS: PC12 cells were treated with L-DOPA at different concentrations. We detected the L-DOPA induced reactive oxygen
Shi-Ying Zhong   +5 more
doaj   +1 more source

The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets

open access: yesJournal of Pharmacological Sciences, 2023
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L-3,4-dihydroxyphenylalanine (L-DOPA)/decarboxylase inhibitor.
Yutaro Ohno   +6 more
doaj   +1 more source

Differential Amperometric Microneedle Biosensor for Wearable Levodopa Monitoring of Parkinson’s Disease

open access: yesBiosensors, 2022
Levodopa (L-Dopa) is considered to be one of the most effective therapies available for Parkinson’s disease (PD) treatment. The therapeutic window of L-Dopa is narrow due to its short half-life, and long-time L-Dopa treatment will cause some side effects
Lu Fang   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy